C.A. Kirby

Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer

George S. Tria, Tinya J. Abrams, Jason R. Baird et al. · Journal of Medicinal Chemistry · 2018 · 123 citations · Full text

Oral Bioavailability, Breast Oncology, Chemoprevention Strategy +16

Identification of NVP-TNKS656: The Use of Structure–Efficiency Relationships To Generate a Highly Potent, Selective, and Orally Active Tankyrase Inhibitor

Michael D. Shultz, Atwood K. Cheung, C.A. Kirby et al. · Journal of Medicinal Chemistry · 2013 · 122 citations · Full text

Drug Target, Selective Tankyrase Inhibitors, Pharmacotherapy +18

Crystal structures of mutant monomeric hexokinase I reveal multiple ADP binding sites and conformational changes relevant to allosteric regulation 1 1Edited by P. E. Wright

Alexander E. Aleshin, C.A. Kirby, Xiaofeng Liu et al. · Journal of Molecular Biology · 2000 · 115 citations

Protein Function, Biochemistry, Natural Sciences +7

ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor

Zineb Mounir, Joshua M. Korn, Thomas Westerling et al. · eLife · 2016 · 73 citations · Full text

[1,2,4]Triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: Antagonists of the Wnt Pathway That Inhibit Tankyrases 1 and 2 via Novel Adenosine Pocket Binding

Michael D. Shultz, C.A. Kirby, Travis Stams et al. · Journal of Medicinal Chemistry · 2012 · 69 citations · Full text

Drug Target, Pharmacotherapy, Tumor Biology +16